2nd Annual Hemophilia Drug Development Summit
Evvnt Promotion / evvnt
Archivio
20.08.2019 - 22.08.2019 Wyndham Boston Beacon Hill, 5 Blossom Street, 02114 Boston, USA
Time: 8:00 am - 5:00 pm
Temi della conferenza
Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.
Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Annotazioni
Brochure: https://go.evvnt.com/411348-2?pid=4832
Speakers: Howard Levy, Chief Medical Officer, Catalyst Biosciences, H. Trent Spencer,President, Expression Therapeutics
Brochure: https://go.evvnt.com/411348-2?pid=4832
Speakers: Howard Levy, Chief Medical Officer, Catalyst Biosciences, H. Trent Spencer,President, Expression Therapeutics
Informazioni ed Iscrizioni:
https://go.evvnt.com/411348-0?pid=4832
Mr. Ilektra Stouka
Sanità Pubblica (Public Health), Servizi sanitari
Lingua
Inglese
Inglese
Quote del Congresso
USD 3.697,00
(USD 1499.0 - USD 3697.0)
USD 3.697,00
(USD 1499.0 - USD 3697.0)
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."
